Valeant Pharmaceuticals International Inc. on Thursday boosted
its outlook for the year after logging strong revenue growth in its
second quarter.
Valeant said it is now forecasting per-share earnings of $11.50
to $11.80, up from its previous guidance of $10.90 to $11.20 a
share. The drug maker is now looking for revenue of $10.7 billion
to $11.1 billion, up from its previous guidance for $10.4 billion
to $10.6 billion.
Valeant completed its $11.1 billion acquisition of Salix
Pharmaceuticals Ltd. earlier this year, after raising its takeover
bid by about a billion dollars in March to knock out rival bidder
Endo International PLC. Salix, which contributed $313 million in
revenue in the latest quarter, makes drugs to treat stomach
disorders, a fast-growing area of specialty pharmaceuticals. Its
drug Xifaxan recently won approval for treatment of irritable bowel
syndrome, which Valeant expects to drive growth throughout the rest
of the year.
In the latest quarter, Valeant said organic growth on a
same-store sales basis was up 19%, driven by strength in its
dermatology, contact lenses and dental businesses.
Overall, for the quarter ended June 30, Valeant reported a loss
of $53 million, or 15 cents a share, compared with a prior-year
profit of $125.8 million, or 37 cents a share.
Excluding foreign exchange and an impact related to Salix,
per-share cash earnings were $2.56 a share.
Revenue surged 34% to $2.73 billion. Excluding the contribution
of Salix and foreign exchange impacts, revenue gained 27%.
Valeant had forecast per-share earnings of $2.40 to $2.50 and
revenue of $2.45 billion to $2.55 billion for the quarter.
The company estimated foreign currency brought down revenue by
$173 million.
Looking to the current quarter, Valeant forecast per-share
earnings of $2.60 to $2.70 a share and revenue of $2.6 billion to
$2.8 billion. Analysts polled by Thomson Reuters had forecast $2.87
a share in earnings and $2.75 billion in revenue.
A serial acquirer, Valeant has grown quickly in recent years by
buying companies with proven drugs, then cutting costs, rather than
depending on risky research in early-stage products. Last week,
Valeant struck a deal to buy Egypt's biggest drug maker, Amoun
Pharmaceutical, for $800 million.
The Wall Street Journal has also reported that Valeant made a
preliminary approach to buy animal-health giant Zoetis Inc.
Write to Chelsey Dulaney at Chelsey.Dulaney@wsj.com
Access Investor Kit for Valeant Pharmaceuticals International,
Inc.
Visit
http://www.companyspotlight.com/partner?cp_code=P479&isin=CA91911K1021
Subscribe to WSJ: http://online.wsj.com?mod=djnwires